Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CEO Emil D. Kakkis bought 7,500 shares of the firm’s stock in a transaction dated Monday, August 28th. The shares were acquired at an average cost of $52.52 per share, with a total value of $393,900.00. Following the completion of the transaction, the chief executive officer now owns 430,569 shares in the company, valued at $22,613,483.88. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Ultragenyx Pharmaceutical Inc. (RARE) opened at 56.24 on Thursday. The stock’s 50 day moving average price is $63.00 and its 200 day moving average price is $66.10. Ultragenyx Pharmaceutical Inc. has a 1-year low of $50.49 and a 1-year high of $91.35. The company’s market cap is $2.39 billion.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.73) by $0.01. During the same period in the previous year, the business posted ($1.46) earnings per share. On average, equities analysts anticipate that Ultragenyx Pharmaceutical Inc. will post ($7.21) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Emil D. Kakkis Purchases 7,500 Shares of Ultragenyx Pharmaceutical Inc. (RARE) Stock” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/08/31/emil-d-kakkis-purchases-7500-shares-of-ultragenyx-pharmaceutical-inc-rare-stock.html.

Large investors have recently bought and sold shares of the company. Ameritas Investment Partners Inc. boosted its stake in Ultragenyx Pharmaceutical by 3.7% in the first quarter. Ameritas Investment Partners Inc. now owns 3,226 shares of the biopharmaceutical company’s stock valued at $219,000 after buying an additional 115 shares during the last quarter. Prudential Financial Inc. boosted its stake in Ultragenyx Pharmaceutical by 5.8% in the first quarter. Prudential Financial Inc. now owns 3,660 shares of the biopharmaceutical company’s stock valued at $248,000 after buying an additional 200 shares during the last quarter. Amalgamated Bank boosted its stake in Ultragenyx Pharmaceutical by 4.6% in the first quarter. Amalgamated Bank now owns 4,628 shares of the biopharmaceutical company’s stock valued at $314,000 after buying an additional 202 shares during the last quarter. Tocqueville Asset Management L.P. boosted its stake in Ultragenyx Pharmaceutical by 8.0% in the second quarter. Tocqueville Asset Management L.P. now owns 3,375 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 250 shares during the last quarter. Finally, Aperio Group LLC boosted its stake in Ultragenyx Pharmaceutical by 8.4% in the second quarter. Aperio Group LLC now owns 3,851 shares of the biopharmaceutical company’s stock valued at $239,000 after buying an additional 299 shares during the last quarter. Institutional investors own 96.18% of the company’s stock.

Several equities research analysts have recently issued reports on RARE shares. Jefferies Group LLC raised their target price on Ultragenyx Pharmaceutical from $66.00 to $68.00 and gave the company a “hold” rating in a research report on Monday, May 8th. Zacks Investment Research lowered Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Stifel Nicolaus reaffirmed a “buy” rating and set a $111.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 30th. Canaccord Genuity reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Monday, May 8th. Finally, Cowen and Company reaffirmed an “outperform” rating on shares of Ultragenyx Pharmaceutical in a research report on Thursday, June 29th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eight have given a buy rating to the company’s stock. Ultragenyx Pharmaceutical presently has a consensus rating of “Hold” and a consensus price target of $74.82.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Insider Buying and Selling by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Stock Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.